This morning when I checked my email, I got an invitation from an international company named OXIS. They are interested to invite me writing about their company and products in this blog. I'm honored to get a trust of this invitation from a big and international company and curious to know more about what their company is offering. Honestly, I've just heard OXIS this morning for the first time and I loved to know more of the new things about them; who they are, what their products are, etc. I went to their website, read and learned a lot about this company. Below I will write what I've read and been interested to introduce them proudly.
Advancing Oxidative Stress Technology OXIS International, Inc (OTCBB: OXIS) is the premier provider for the potent antioxidant, Ergothioneine and through their patented synthetic manufacturing process remains the only significant commercial source of pure I-ergothioneine worldwide.
OXIS was founded in 1966 and for many years focused on diagnostics while developing some of its unique patented compounds and acquiring significant expertise in the field of oxidative stress including ERGO. It is engaged in the research, development and sale of products that counteract the harmful effects of “oxidative stress.” Oxidative stress refers to the situations in which the body’s antioxidant and other defensive abilities to combat free radicals (a.k.a highly reactive species of oxygen and nitrogen) are overwhelmed and one’s normal healthy balance is either lost or severely compromised.
OXIS is developing and plans to sell Nutraceutical and Cosmecuetical products featuring natural ingredients believed to have beneficial effects on human health. OXIS’ consumer products strategy addresses very important health concerns including aging and age-related disorders that are increasing with trends in US demographics. These concerns include brain health, immunity against diseases, anti-aging/skin health, inflammation, detoxification, and blood sugar regulation.
Their products include therapeutic nutraceutical products, cosmeceutical products and proprietary formulations and clinical products that are developed internally and/or out-licensed to biotech and pharmaceutical companies as drug candidates.
Talking about ERGO, it is a new word for me, so I kept reading what it is about.
ERGO (Ergothioneine--the super anti-oxidant) is naturally occurring, water soluble, amino acid multifaceted antioxidant produced by microbes in the soil and most commonly found in (but not produced by) various species of mushrooms and grapes, meats and dairy products. However, it is not commercially practical to extract ERGO from these natural sources and it essentially impossible to ingest a diet that provides enough ERGO to take full advantage of its potential health benefits. Humans and most animals typically have low levels of ERGO since the amount of ERGO in the diet is relatively small.
Some of the potential benefits of ERGO include its ability to:
* Conserve and maintain the levels of other antioxidants such as Vitamin E, Vitamin C and glutathione;
* Increase respiration and the oxidation of fat (possibly contributing to increased energy and exercise capacity);
* Protect mitochondria from damage (this is important because potentially damaging reactive oxygen species are generated when oxygen is normally metabolized in mitochondria;
* Reduce the damaging effects of environmental ultraviolet radiation (likely to be important in protecting the eyes against cataract producing oxidative injury);
* Neutralize increased oxidative stress by providing an ROS (reactive oxygen species) and RNS (reactive nitrogen species) scavenging capacity, a property that protects key molecules in the body; and,
* Protect against the effects of neurotoxins that are believed to have a casual role in the development and progression of cognitive decline.
OXIS is completing a strategic and timely transformation towards its goal of becoming a leading nutraceutiecal, cosmecuetical and therapeutics company and now focusing its business on its rich science background and its related 12 key patents and 7 patent pending applications and other new research.
During the past twelve months, OXIS has made significant strides towards its new objectives including divesting all of it diagnostics businesses to strategically focus the business on neutraceuticals, cosmeceuticals and therapeutic compounds; Building a new strong team of Executive Management, Board of Directors, and Scientific Advisory Board; Raising new capital to fund its new strategy; and Increasing the equity value and liquidity of its common/penny stock and regaining Bulletin Board trading status.
If you're the investors and others interested in learning more about OXIS are invited to review the following additional information such as Investor Presentation, Whistleblower Policy, Code of Ethics, and Investor Presentation.
For additional technical information on their therapeutic compounds and/or to discuss licensing opportunities, you should contact them via email or send them a letter via mail at 468 N. Camden Dr., 2nd Floor Beverly Hills CA 90210 USA or you may call them at (310) 860-5184.
They're also available to reach at several international social media: Twitter, Flickr and Facebook. ***
Oxis on Twitter
Oxis on facebook
What am I doing right now?
Follow me at Twitter
I'm going to prepare several things for my book signing and continue to write my 2nd cookbook.
about 1 minute ago from web